STRS Ohio’s Kalaris Therapeutics KLRS Stock Holding History

STRS Ohio’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-196	Closed	-$123K	–	2298
2020 Q3	$123K	Buy	+196	New	+$134K	﹤0.01%	1795

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

STRS Ohio's KLRS Position: Q4 2020 in Review

STRS Ohio sold out of Kalaris Therapeutics (KLRS) in Q4 2020, closing a stake of 196 shares — an estimated $123K sold.

STRS Ohio first reported a position in KLRS in Q3 2020 and held it in 1 quarter. The position peaked at $123K in Q3 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q4 2020.

STRS Ohio reported no remaining Kalaris Therapeutics position as of Q4 2020 after selling out during the quarter.
STRS Ohio sold 196 Kalaris Therapeutics shares in Q4 2020, an estimated $123K.
STRS Ohio first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 1 quarter.
STRS Ohio's Kalaris Therapeutics position peaked at $123K in Q3 2020.
71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2020.

Based on STRS Ohio's 13F filing for Q4 2020, filed 25 Jan 2021.